Want to join the conversation?
$ESRX's 3Q15 adjusted EBITDA increased 4% year-over-year as a result of managing specialty, formulary management and an increase in the aggregate generic fill rate. Adjusted SG&A expenses increased 2% year-over-year. Adjusted EBITDA per claim was $5.51, an increase of 4% year-over-year. $ESRX deployed approx. $1.2Bil of cash to repay debt in 3Q15.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.